Pyxis Oncology's (PYXS) "Outperform" Rating Reiterated at Royal Bank of Canada

Pyxis Oncology (NASDAQ:PYXS - Get Free Report)'s stock had its "outperform" rating reaffirmed by equities researchers at Royal Bank of Canada in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $8.00 price objective on the stock, down from their prior price objective of $10.00. Royal Bank of Canada's price target would suggest a potential upside of 373.37% from the company's current price.

A number of other brokerages have also recently issued reports on PYXS. HC Wainwright reissued a "buy" rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Thursday, November 21st. William Blair cut Pyxis Oncology from an "outperform" rating to a "market perform" rating in a research report on Thursday, November 21st. Finally, Stephens began coverage on Pyxis Oncology in a research note on Friday, November 8th. They set an "overweight" rating and a $13.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $9.43.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock traded up $0.15 during trading on Friday, hitting $1.69. 1,773,492 shares of the company's stock traded hands, compared to its average volume of 795,458. The company has a market cap of $100.50 million, a PE ratio of -1.64 and a beta of 1.00. The firm's fifty day moving average price is $2.93 and its 200 day moving average price is $3.30. Pyxis Oncology has a twelve month low of $1.49 and a twelve month high of $6.85.

Insiders Place Their Bets

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the stock in a transaction on Tuesday, November 26th. The stock was purchased at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the transaction, the chief financial officer now owns 1,199,143 shares of the company's stock, valued at $2,350,320.28. The trade was a 8.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.80% of the company's stock.

Hedge Funds Weigh In On Pyxis Oncology

A number of large investors have recently modified their holdings of PYXS. Fullcircle Wealth LLC acquired a new position in shares of Pyxis Oncology during the second quarter valued at $40,000. Bank of New York Mellon Corp lifted its position in Pyxis Oncology by 92.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company's stock valued at $1,031,000 after purchasing an additional 149,522 shares during the period. Rhumbline Advisers bought a new position in shares of Pyxis Oncology in the 2nd quarter valued at about $216,000. Pier 88 Investment Partners LLC boosted its stake in shares of Pyxis Oncology by 121.4% in the 2nd quarter. Pier 88 Investment Partners LLC now owns 113,700 shares of the company's stock valued at $376,000 after purchasing an additional 62,340 shares during the last quarter. Finally, American Century Companies Inc. grew its position in shares of Pyxis Oncology by 56.0% during the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company's stock worth $193,000 after buying an additional 20,901 shares during the period. 39.09% of the stock is currently owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.